An Extension to Study MD7108240

NCT00733304 | Completed Phase 2 Results

• 1 other identifier: MD7111396
• Study Type: interventional
• Target: 42
• Locations: 3 countries
• Sites: 17

Brief Summary

This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.

Conditions

Macular Degeneration

Keywords

age-related macular degeneration (AMD); choroidal neovascularization (CNV); vascular endothelial growth factor (VEGF); pazopanib; angiogenesis

Outcome Measures

Primary Outcomes (21)

• Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period

  Change from Baseline is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. SBP and DBP were recorded from Baseline up to 6 months. At screening and Baseline, if the single measured value of blood pressure was above 150 millimeters of mercury (mm Hg) systolic or 95 mm Hg diastolic, then blood pressure measurement could not be repeated. If, the SBP was \<80 or \>140 mm Hg and DBP was \<40 or \>90 mm Hg, then measurement of BP was repeated. Three consecutive blood pressure readings that were less than 150 mmHg systolic and 95 mmHg diastolic were taken with each measurement separated by at least 1 hour.

  Baseline (Day 1) and approximately up to 6 months

• Change From Baseline (Day 1) in Heart Rate Over Period

  Heart rate was measured over 6 months. Baseline value was recorded on Day 1. Change from Baseline is the value at indicated time point minus the Baseline value. Heart rate measurement were repeated in case it was in range \< 50 beats per minute (bpm) or \>110 bpm.

  Baseline (Day 1) and approximately up to 6 months

• Change From Baseline (Day 1) in Albumin and Hemoglobin Over Period

  Albumin and hemoglobin values were recorded at Baseline, Month2, and till follow-up (Month 6). Baseline was recorded on Day 1. Change from Baseline is the value at indicated time point minus the Baseline value.

  Baseline (Day 1), Month 2, 5 and approximately up to Month 6

• Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferases (ALT), and Aspartate Aminotransferases (AST) Over Period

  ALP, ALT and AST values were measured over 5 months and till the follow-up period. Baseline value was recorded pre-dose Day 1. Change from Baseline is the value at indicated time point minus the Baseline value.

  Baseline (Day 1) and approximately up to 6 months

• Change From Baseline (Day 1) in Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets, and White Blood Cell Count Over Period

  Change from Baseline is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. The above mentioned hematological parameters were recorded from Baseline up to 5 months.

  Baseline (Day 1) and approximately up to 6 months

• Change From Baseline (Day 1) in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils Over Period

  Change from Baseline is the value at indicated time point minus the Baseline value. Over here, the change is % Basophils at month x - % Basophils at Baseline. Baseline measurement was recorded at Day 1. Percentage change in the hematological parameter mentioned above was recorded from Baseline up to 5 months.

  Baseline (Day 1) and approximately up to 6 months

• Change From Baseline (Day 1) in Direct Bilirubin, Total Bilirubin, and Creatinine Over Period

  Change from Baseline is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. Direct bilirubin, total bilirubin, and creatinine were recorded from Baseline up to 6 months

  Baseline (Day 1) and approximately up to 6 months

• Change From Baseline in Calcium, Chloride, Carbon di Oxide Equivalent Content, Glucose, Potassium, Sodium, and Urea Blood Urea Nitrogen (BUN) Over Period

  Change from Baseline (Day 1) is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. Calcium, chloride, carbon di oxide equivalent content (CO2), glucose, potassium, sodium, and urea/blood urea nitrogen (BUN) was recorded from Baseline up to Follow-up.

  Baseline (Day 1) and approximately up to 6 months

• Change From Baseline (Day 1) in Mean Corpuscular Volume (MCV) Over Period

  Change from Baseline is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. MCV was recorded from Baseline up to Follow-up.

  Baseline (Day 1) and approximately up to 6 months

• Change From Baseline (Day 1) in Intra-ocular Pressure Assessment Over Period

  Change from Baseline is the value at indicated time point minus the Baseline value. Baseline measurement was recorded at Day 1. Intra-ocular pressure was recorded from Baseline up to Follow-up.

  Baseline (Day 1) and approximately up to 6 months

• Number of Participants With Blood Occult, Urine Glucose, Urine Ketones, and Urine Proteins by Dip Stick Analysis

  In this dipstick test, the level of blood occult and glucose, ketones, protein in urine samples were recorded as negative, trace, 1+, 2+, and 3+ (the plus sign increases with a higher level of glucose, ketones, or proteins in the urine: 1+=slightly positive, 2+=positive, 3+=high positive).

  Approximately up to 6 months (up to follow-up)

• Number of Participants With Adverse Events (AEs)and Serious Adverse Events (SAEs)

  Number of participants with ocular and non-ocular AEs and SAEs were separately recorded. An AE is an unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain time period after the study has ended. This change may or may not be caused by the intervention being studied. An SAE is an adverse event that results in death, is life-threatening, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect. Medical events that do not result in death, are not life-threatening, or do not require hospitalization may be considered serious adverse events if they put the participant in danger or require medical or surgical intervention to prevent one of the results listed above.

  Approximately up to 6 months

• Number of Participants With Abnormal Visual Acuity of Potential Clinical Concern (PCI)

  Visual acuity was measured over 5 months and also during follow-up period. Visual acuity was measured using standardized early treatment of diabetic retinopathy study (ETDRS) visual acuity charts. Visual acuity measurement was performed by an examiner that had been appropriately trained. Screening, Month 2 and Month 5 data were considered as Best Corrected Visual Acuity (BCVA) data. A loss of greater than or equal to 15 letters in BCVA from Baseline was considered of PCI. Data for number of participants who met the criteria for PCI have been presented.

  Approximately up to 6 months

• Number of Participants With Abnormal Pupil Examination of PCI

  Pupil abnormalities were of different types. Meibomian gland dysfunction was measured as obvious inspissation (debris). Mild injection, no trichiasis (lid thickening), or two step worsening was analyzed. Afferent pupillary defect, motility examination, PERRL, confrontation visual field was measured as a new definite abnormality. Left and right both eyes were examined.

  Up to follow-up (approximately 6 months)

• Number of Participants With Abnormal Conjunctival Examination of PCI

  A two step worsening in the conjunctival examination was considered a value of PCI. Participants were analyzed for conjunctival examination up to follow-up (6 months).

  Up to follow-up (approximately 6 months)

• Number of Participants With Abnormal Anterior Chamber Examination of PCI

  A two step worsening in the anterior chamber examination was considered a value of PCI. The participants were examined for any anterior chamber abnormality. Fibrinous response and obvious aqueous haze were considered abnormalities related to anterior chamber examination.

  Approximately up to 6 months

• Number of Participants With Abnormal Corneal Examination of PCI

  A two step change in any of the lens opacity categories was categorized as of PCI. Corneal epithelium was defined as abnormal when punctate keratopathy was measured as mild, moderate, severe; epithelial edema was measured as subtle epithelial haze, mild patchy microcystic changes, diffuse microcystic changes, and/or investigator determined abnormality. Stromal opacity/ edema was measured by investigator when stroma identifies opacity or edema. Corneal staining was measured as obvious (\<=20) localized or diffuse punctate staining areas, severe localized or diffuse punctate staining. Participants were analyzed for any of the mentioned abnormality over 6 weeks (up to follow-up period).

  Approximately up to 6 months

• Number of Participants With Abnormal Lens Opacity of PCI Using Age Related Eye Disease Study (AREDS) Scale

  A two step change in any of the lens opacity categories was considered a value of PCI. Aphakia (surgical removal of lens) or pseudophakia was noted if any. Stroma opacity or edema was measured by investigator when it was detected as edema or opacity in stroma.

  Approximately up to 6 months

• Number of Participants With Abnormal Tear Films of PCI

  Tear film abnormalities were based on the clinical judgment of investigator. Tear film thickness was analyzed and it was reported whether the film was increased or decreased or was normal. Presence of debris or mucus was also reported. Other test were tear lake analysis and checking of discharge from eyes.

  Approximately up to 6 months

• Number of Participants With Any Grade 2 Plus Worsening of Meibomian Gland Function

  Meibomian gland dysfunction was measured as obvious insipisation/debris, mild injection, no trichiasis or lid thickening; inspisation, debris, obvious injection, lid thickening, may have trsichiasis; or a two step worsening. Any 2+ worsening of Meibomian gland function was considered a value of PCI.

  Approximately up to 6 months

• Number of Participants With Abnormal (Dilated) Fundus Examination

  Dilation of fundus was examined post dosing up to 6 months. Number of participants with abnormal change from Baseline indicating dilation of fundus of eye was reported. Change from Baseline was the value at indicated time point minus the Baseline value. The abnormalities were posterior vitreous separation, pale optic nerve, fluid in the posterior pole, drusen, thick arterio-venous changes, pigment changes, cystoids, macular edema, drying of posterior fluid or sub-retinal fluid, underlying central atrophy, and retinal pigment epithelial changes etc. Refraction measurement were determined at the screening and 2 month/5 month visits in order to determine BCVA.

  Approximately up to 6 months

Secondary Outcomes (4)

• Change From Baseline (Screening Visit) in BCVA at Month 2 and 5

  From Baseline (screening visit), Month 2, and Month 5

• Change From Baseline (Screening Visit) in Optical Coherence Tomography (OCT) Central Subfield Over 5 Months

  From Baseline (Screening visit) and up to 5 months

• Change in Neo-vascular Size and Lesion Size Over Period

  Up to 6 weeks

• Number of Participants With Lesion Types Over Period

  Up to 6 months

Study Arms (3)

5 mg/ml TID

EXPERIMENTAL

eligible participants received 5 mg/ml Pazopanib eye drops three times daily (TID)

Drug: Pazopanib

2 mg/ml TID

EXPERIMENTAL

eligible participants received 2 mg/ml Pazopanib eye drops three times daily

Drug: Pazopanib

5 mg/ml QD

EXPERIMENTAL

eligible participants received 5 mg/ml Pazopanib eye drops once daily (QD)

Drug: Pazopanib

Interventions

Pazopanib DRUG

5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD

2 mg/ml TID; 5 mg/ml QD; 5 mg/ml TID

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects who participated in Phase IIa study MD7108240 and who did not experience AMD disease progression requiring rescue therapy during pazopanib treatment or require discontinuation of pazopanib eye drops for safety reasons
• Best-corrected ETDRS visual acuity in the study eye of 23 letters (20/320 or 4/63) or better at screening.
• QTcB or QTcF \< 450msec; or QTc \< 480msec in subjects with Bundle Branch Block.
• Subject is willing and able to return for all study visits, and is willing and able to comply with all protocol requirements and procedures.
• Subject is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. If the subject is unable to read the consent form due to visual impairment then the consent must be read to the subject verbatim by person administering the consent, a family member or legally acceptable representative. If the subject is unable to provide written informed consent due to visual impairment, then written informed consent on behalf of the subject must be provided by a legally acceptable representative. (Note: Consent by legally acceptable representative is allowed where this is in accordance with local laws, regulations and ethics committee policy.)

You may not qualify if:

• Anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation of the fundus for photographs, fluorescein angiography and OCT.
• Vitreous, subretinal or retinal hemorrhage in the study eye that is unrelated to AMD.
• Intraocular surgery in the study eye within 3 months of dosing.
• Use of topical ocular medications (other than pazopanib) in the study eye within 7 days of first dose of investigational product or expected use of topical ocular medications during the treatment period, with the exception of artificial tears.
• Current use of medications known to be toxic to the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol).
• An unwillingness to refrain from wearing contact lenses starting from the screening visit, through the follow-up visit
• ALT or AST above the upper limit of normal or total bilirubin ≥ 1.5 times the upper limit of normal at baseline. Note: Laboratory tests outside of the normal range may be repeated at the discretion of the Investigator.
• Medical history or condition:
• Uncontrolled Diabetes Mellitus, with hemoglobin A1c (HbA1c) \> 10%.
• Myocardial infarction or stroke within 6 months of screening.
• Active bleeding disorder.
• Major surgery within 1 month of screening.
• Hepatic impairment.
• Uncontrolled hypertension, based on criteria provided in the protocol. Note: Initiation or adjustment of antihypertensive medications is permitted prior to study entry provided the referenced criteria are met.
• Use of prohibited medications listed in the protocol within the restricted timeframe relative to the first dose of study medication.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (17)

GSK Investigational Site

Beverly Hills, California, 90211, United States

Location

GSK Investigational Site

Sacramento, California, 95841, United States

Location

GSK Investigational Site

Winter Haven, Florida, 33880, United States

Location

GSK Investigational Site

Indianapolis, Indiana, 46280, United States

Location

GSK Investigational Site

Boston, Massachusetts, 02111, United States

Location

GSK Investigational Site

Ann Arbor, Michigan, 48105, United States

Location

GSK Investigational Site

Grand Rapids, Michigan, 49525, United States

Location

GSK Investigational Site

Salt Lake City, Utah, 84132, United States

Location

GSK Investigational Site

Sydney, New South Wales, 2145, Australia

Location

GSK Investigational Site

Sydney, New South Wales, 2150, Australia

Location

GSK Investigational Site

Melbourne, Victoria, Australia

Location

GSK Investigational Site

Perth, Western Australia, 6009, Australia

Location

GSK Investigational Site

Milan, Lombardy, 20132, Italy

Location

GSK Investigational Site

Milan, Lombardy, 20157, Italy

Location

GSK Investigational Site

Turin, Piedmont, 10122, Italy

Location

GSK Investigational Site

Florence, Tuscany, 50134, Italy

Location

GSK Investigational Site

Padua, Veneto, 35128, Italy

Location

MeSH Terms

Conditions

Macular Degeneration; Choroidal Neovascularization

Interventions

pazopanib

Condition Hierarchy (Ancestors)

Retinal Degeneration; Retinal Diseases; Eye Diseases; Choroid Diseases; Uveal Diseases; Neovascularization, Pathologic; Metaplasia; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 12, 2008
• First Posted: August 13, 2008
• Study Start: June 25, 2008
• Primary Completion: September 9, 2009
• Study Completion: September 9, 2009
• Last Updated: December 5, 2017
• Results First Posted: December 5, 2017

Record last verified: 2017-10

Locations

IT (5); US (8); AU (4)